{"doi":"10.1089/dia.2022.0447","title":"Increased Derived Time in Range Is Associated with Reduced Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and Microvascular Events in Type 2 Diabetes: A Post Hoc Analysis of DEVOTE","abstract":"Time spent in glycemic target range (time in range [TIR]; plasma glucose 70–180 mg/dL [3.9–10.0 mmol/L]) as a surrogate endpoint for long-term diabetes-related outcomes requires validation. This post hoc analysis investigated the association between TIR, derived from 8-point glucose profiles (derived TIR [dTIR]) at 12 months, and time to cardiovascular or severe hypoglycemic episodes in people with type 2 diabetes in the DEVOTE trial. At 12 months, dTIR was significantly negatively associated with time to first major adverse cardiovascular event ( P = 0.0087), severe hypoglycemic episode ( P < 0.0001), or microvascular event ( P = 0.024). A nonsignificant trend was seen toward association between 12-month hemoglobin A1c (HbA1c) and these outcomes, but this was no longer seen after addition of dTIR to the model. The results support targeting TIR >70% and suggest dTIR could be used in addition to, or in some instances in place of, HbA1c as a clinical biomarker. Trial registration details: ClinicalTrials.gov, NCT01959529","journal":"Diabetes Technology & Therapeutics","year":2023,"id":322687,"datarank":1.6376992691701746,"base_score":3.6888794541139363,"endowment":3.6888794541139363,"self_citation_contribution":0.5533319181170905,"citation_network_contribution":1.084367351053084,"self_endowment_contribution":0.5533319181170905,"citer_contribution":1.084367351053084,"corpus_percentile":null,"corpus_rank":null,"citation_count":39,"citer_count":32,"citers_with_citation_signal":18,"citers_with_endowment":18,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9177,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT01959529"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":419711,"name":"ELISE HACHMANN-NIELSEN","orcid":"0000-0001-5110-9880","position":1,"is_corresponding":false},{"id":421055,"name":"Kajsa Kvist","orcid":null,"position":2,"is_corresponding":false},{"id":231684,"name":"Anne L. Peters","orcid":"0000-0003-0520-0776","position":3,"is_corresponding":false},{"id":1037426,"name":"Jens M. Tarp","orcid":null,"position":4,"is_corresponding":false},{"id":34495,"name":"John B. Buse","orcid":"0000-0002-9723-3876","position":5,"is_corresponding":false},{"id":243049,"name":"Richard M. Bergenstal","orcid":"0000-0002-9050-5584","position":0,"is_corresponding":true}],"reference_count":18,"raw_metadata":null,"created_at":"2026-07-19T01:07:47.432636Z","pmid":"37017470","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}